Growing evidence supports integrating lifestyle interventions into oncology practice, showing benefits in recurrence reduction, mortality improvements, and cost savings. Novel therapies emerge such as vepdegestrant demonstrating superior efficacy versus fulvestrant in mutant ER+ breast cancer. The EHA–EMN released new guidelines transforming smoldering multiple myeloma care. Research on epithelial–mesenchymal transition elucidates mechanisms driving metastasis and therapy resistance. These developments collectively enrich precision oncology, blending clinical practice changes with molecular and therapeutic insights.